Last reviewed · How we verify

epinephrine and levosimendan — Competitive Intelligence Brief

epinephrine and levosimendan (epinephrine and levosimendan) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inotropic agent combination. Area: Cardiovascular.

marketed Inotropic agent combination Adrenergic receptors (alpha-1, beta-1) and cardiac troponin C Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

epinephrine and levosimendan (epinephrine and levosimendan) — Federal University of Juiz de Fora. This combination uses epinephrine's alpha and beta-adrenergic stimulation alongside levosimendan's calcium sensitization to enhance cardiac contractility and improve hemodynamics in acute heart failure.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
epinephrine and levosimendan TARGET epinephrine and levosimendan Federal University of Juiz de Fora marketed Inotropic agent combination Adrenergic receptors (alpha-1, beta-1) and cardiac troponin C

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inotropic agent combination class)

  1. Federal University of Juiz de Fora · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). epinephrine and levosimendan — Competitive Intelligence Brief. https://druglandscape.com/ci/epinephrine-and-levosimendan. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: